Insider buying last 90 days
No open-market insider purchases were filed for ONC in the last 90 days.
From Form 4 filings, dated to when each was filed.
Every ONC insider filing, plotted on the chart in Gekko.Open ONC in Gekko
BeOne Medicines (ONC) Stock Analysis & Forecast
$350.84−2.62 (−0.7%)
Close on Sep 18, 2026. Page updated Sep 19, 9:19 pm ET.
Gekko Brief
AI summaryONC closes at $350.84, down 0.7%, holding above both its 50-day ($343.13) and 200-day ($318.13) averages, with the shorter average above the longer one. The GekkoIndex reads 60.5, placing the stock in the Accumulation zone, though the reading has slipped 3.5 points over five days. Price sits 7.4% below Gekko Fair Value of $379.
This week's attention centers on BeOne Medicines' presentation at the Morgan Stanley 24th Annual Global Healthcare Conference on 14 September, alongside continued analyst engagement. Barclays reiterated its Buy rating on 11 September and raised its price target to $415 from $400, citing confidence in the company's pharmaceutical performance. Separately, an insider sale was disclosed: Xiaodong Wang sold 38,287 shares on 8 September at an average price of $349.10, for a total value of $13,365,991.70.
The next earnings report is set for 5 November 2026, before the open, 46 days out and beyond a typical 20-trading-day holding window. The prior quarter saw EPS of $2.05 against an estimate of $1.40, with a 2.1% reaction, and the company has beaten estimates in 6 of the last 8 quarters, with an average absolute reaction of 4.3%. No insider, Congress, or unusual options activity appears in the current window. Seasonally, the next 20 trading days from this point have averaged -2.5% over 5 years, with gains in 2 of those years — a pattern worth noting against the current Accumulation-zone backdrop, where that zone has historically preceded a 20-day average return of 8.2%.
Written by AI and checked automatically against the figures on this page. Generated Sep 20, 2026 from the data above.
Price vs fair value
Close $350.84200-day averageGekko Fair Value $379.00
Key stats
- Market cap
- $37.49B
- P/E ratio
- 62.9
- Forward P/E
- 34.1
- EPS, TTM
- $5.58
- Revenue, TTM
- $6.13B
- Profit margin
- 10.7%
- Dividend yield
- —
- Beta
- 0.52
- Volume
- 434,601 avg 333,333
- 1-year return
- +5.6%
- Typical daily move
- ±2.5%
- Typical 20-day move
- ±9.9%
- 50-day average
- $343.13
- 200-day average
- $318.13
- Next earnings
- Nov 5 before open
- Shares outstanding
- 104.3M
BeOne Medicines swing-trade checklist
BeOne Medicines scores 4 supportive, 0 mixed and 1 headwind across the 5 checklist items with data.
Six things swing traders check before a 20-day hold, read from the latest data.
4 supportive0 mixed1 headwind
- Trendsupportive
Above 50 and 200-day
Close $350.84 is above the 50-day ($343.13) and 200-day ($318.13) averages, and the 50-day is above the 200-day.
See the chart - GekkoIndexsupportive
60.5, Accumulation
Reading 60.5 is in the Accumulation zone.
See the GekkoIndex - Fair valuesupportive
7.4% below
Price is 7.4% below Gekko Fair Value (more than 5% below).
See fair value - Smart moneyno data
No data
No insider, Congress or unusual options activity in the window.
See smart money - Earnings risksupportive
Reports in 46 days
Next report Nov 5, 2026, 46 days away — outside a typical 20-trading-day hold.
See earnings - Seasonalityheadwind
−2.5% on average
From this point in the calendar, the next 20 trading days averaged −2.5% over 5 years, rising in 2 of them.
See seasonality
A description of current data, not a recommendation. How this page works
BeOne Medicines stock chart and price history
BeOne Medicines closed at $350.84 on Sep 18, 2026, +5.6% over the past year, inside a 52-week range of $253.95 to $385.22.
Close50-day average200-day averageVolume
Use the left and right arrow keys to read daily values.
Performance Breakdown
- 1 month
- −6.9%
- 3 months
- +29.9%
- 6 months
- +24.1%
- 1 year
- +5.6%
The full ONC chart adds GekkoIndex, insider, options, Congress and hedge fund markers, plus TrendCandles™.Open ONC in Gekko
Follow BeOne Medicines through every session
Put ONC on a Gekko watchlist and see its GekkoIndex, Gekko Fair Value and smart money signals update on the chart as they change.
Track ONC in GekkoFree for 7 days. No credit card required.
About BeOne Medicines
BeOne Medicines focuses on finding and developing treatments for cancer patients, with reach into the United States, China, Europe and other regions. Its marketed products include BRUKINSA, a treatment for several blood cancers; TEVIMBRA, an immunotherapy used against various solid tumors and blood cancers; SYLVANT, for adults with multicentric castleman disease; BAITUOWEI, used in certain breast cancer cases; and PARTRUVIX, for various solid tumors.
Beyond these approved therapies, the company runs a broad pipeline of experimental compounds targeting different cancer pathways, alongside earlier-stage preclinical work. It has established agreements with other pharmaceutical companies, including Amgen, BMS, Bio-Thera, EUSA Pharma, Luye Pharmaceutical, and Novartis, reflecting collaborative ties across its research and development efforts.
The company was founded in 2010 and is headquartered in Basel, Switzerland. It previously operated under the name BeiGene, Ltd. before adopting its current name in May 2025. Its shares trade under the ticker ONC.
- Sector
- Health technology
- Website
- beonemedicines.com
BeOne Medicines GekkoIndex: the smart money zone
BeOne Medicines’s GekkoIndex — Gekko’s 0 to 100 smart money score — reads 60.5, in the Accumulation zone, down 3.5 points over five sessions.
60.5Accumulation
Down 3.5 points over five sessions.
Reading for Sep 18, 2026
What followed past readings in each zone
| Zone | Readings | 5 days | 20 days |
|---|---|---|---|
| Buying | 43 | +2.4% | +10.4% |
| Accumulation (current zone) | 160 | +1.4% | +8.2% |
| Neutral | 315 | +0.7% | +1.1% |
| Distribution | 83 | −0.2% | +2.2% |
| Selling | 14 | −0.7% | −4.3% |
Average ONC share-price change over the trading days after each daily reading in its GekkoIndex history. Across every stock Gekko tracks, Accumulation readings averaged +2.3% over 20 days. Past behaviour doesn’t guarantee future results.
Accumulation zone: Institutional interest building. About the five zones →
See every daily GekkoIndex reading plotted over the ONC price, zone by zone.Track ONC in Gekko
Is BeOne Medicines stock overvalued? Gekko Fair Value
BeOne Medicines trades 7.4% below Gekko Fair Value of $379.00, so the shares are undervalued on Gekko’s estimate.
Gekko’s own estimate of what BeOne Medicines shares are worth, recalculated every trading day.
$379.00
Gekko Fair Value, Sep 19, 2026
7.4% Undervalued
Gekko Fair Value on every chart, with the gap to price updating daily.Open ONC in Gekko
BeOne Medicines insider and Congress trading
No open-market insider purchases were filed for BeOne Medicines, and no Congress trades were disclosed, in the last 90 days.
Plus buybacks, unusual options and fund positions, each dated to when it became public.
Congress trades last 90 days
No trades in ONC were disclosed by members of Congress in the last 90 days.
From congressional disclosures, which report amounts as ranges.
Congress disclosures for ONC, plotted on the chart in Gekko.Open ONC in Gekko
BeOne Medicines earnings: next date and track record
BeOne Medicines reports on Nov 5, 2026, before the open (46 days away), and beat the EPS estimate in 6 of its last 8 reports.
Next earnings report
Nov 5, 2026
Expected before the open, 46 days away
- EPS estimate
- $1.90
- Revenue estimate
- $1.75B
6 of 8reports beat the EPS estimate
±4.3%average move across the report
3 of 8reports followed by a gain
Share-price move across each report
Last earnings call, Aug 5, 2026 AI summary
- What they said
- BeOne Medicines reported Q2 2026 total revenues of $1.7 billion, up 30% YoY, with GAAP EPS of $2.05 per ADS, up 144% YoY. BRUKINSA exceeded $1.2 billion in quarterly global revenues, growing 31% YoY, maintaining its position as the #1 BTK inhibitor globally. Key milestones include FDA approval of BEQALZI for mantle cell lymphoma and positive Phase III MANGROVE trial results. A $300 million U.S. manufacturing expansion was also announced.
- Guidance
- Management raised 2026 revenue guidance by $300 million and GAAP operating income guidance by $250 million on the strength of Q2 results. Global regulatory submissions for BRUKINSA in frontline MCL are planned for H2 2026, with four additional Phase III readouts expected over the next three years.
| Reported | EPS | Revenue | Move |
|---|---|---|---|
| Aug 5, 2026 | $2.05 est $1.40 | $1.71B est $1.62B | +2.1% |
| May 6, 2026 | $1.96 est $0.81 | $1.51B est $1.48B | +6.6% |
| Feb 26, 2026 | $0.58 est $1.60 | $1.50B est $1.47B | −10.0% |
| Nov 6, 2025 | $1.09 est $0.72 | $1.41B est $1.45B | −0.4% |
| Aug 6, 2025 | $0.84 est $0.48 | $1.32B est $1.44B | −2.9% |
| May 7, 2025 | $1.22 est −$0.71 | $1.12B est $1.25B | −2.4% |
| Feb 27, 2025 | −$1.43 est −$1.01 | $1.13B est $1.04B | +4.9% |
| Nov 12, 2024 | −$0.09 est −$1.04 | $1.00B | −4.7% |
“Move” is the close of the first session after the report compared with the close of the last session before it, so it reads the same whether the company reported before the open or after the close.
BeOne Medicines stock forecast and analyst price targets
Analysts’ average 12-month price target for BeOne Medicines is $432.80, +23.4% from the last close, from 14 firms rating the stock in the last 90 days.
$432.80consensus 12-month target, +23.4% from the last close
Now $350.84Avg $432.80
Low $370High $466
Each firm’s latest rating in the last 90 days: 14 firms.
Latest analyst actions
| Date | Firm | Target | vs price |
|---|---|---|---|
| Sep 10 | Barclays | $415 | +18.3% |
| Aug 25 | RBC Capital | $450 | +28.3% |
| Aug 9 | Wolfe Research | $370 | +5.5% |
| Aug 7 | CMB International Securities | $442.31 | +26.1% |
| Aug 6 | Morgan Stanley | $405 | +15.4% |
+8.2%average 20-day move after past Accumulation readings
−2.5%average move over the next 20 trading days in the last 5 years
±2.5%typical daily move, from the 14-day average range
Gekko doesn’t publish price predictions. These are analyst targets and historical base rates, which don’t guarantee future results.
BeOne Medicines seasonality: the next 20 trading days
Over the next 20 trading days from Sep 19, BeOne Medicines averaged −2.5% across the last 5 years, rising in 2 of them.
Next 20 trading days, by year
Average move and hit rate
| Window | Average | Years higher |
|---|---|---|
| Next 5 trading days | −5.8% | 1 of 5 |
| Next 10 trading days | −3.6% | 2 of 5 |
| Next 15 trading days | −4.4% | 1 of 5 |
| Next 20 trading days | −2.5% | 2 of 5 |
| Next 30 trading days | −2.9% | 2 of 5 |
For scale, ONC’s typical 20-trading-day move in either direction is about 9.9%.
BeOne Medicines market cap and key statistics
BeOne Medicines’s market cap is $37.49B, with a P/E ratio of 62.9 and revenue of $6.13B over the last twelve months.
Valuation
- Market cap
- $37.49B
- P/E ratio
- 62.9
- Forward P/E
- 34.1
- EPS, TTM
- $5.58
- Gekko Fair Value
- $379.00
Trading
- Volume
- 434,601
- Avg volume, 20 days
- 333,333
- 52-week high
- $385.22
- 52-week low
- $253.95
- Shares outstanding
- 104.3M
Financials
- Revenue, TTM
- $6.13B
- Profit margin
- 10.7%
- Return on equity
- 14.7%
- Quarterly earnings growth, YoY
- +166.7%
Risk and income
- Beta
- 0.52
- Typical daily move
- ±2.5%
- Typical 20-day move
- ±9.9%
BeOne Medicines stock news this week
3 headlines about BeOne Medicines from the past week, newest first, each linking to the publisher.
- BeOne Medicines AG (ONC) Presents at Morgan Stanley 24th Annual Global Healthcare Conference TranscriptSeeking Alpha, Sep 14
- BeOne Medicines (NASDAQ:ONC) Insider Sells $13,365,991.70 in StockDefense World, Sep 13
- Barclays Maintains BeiGene(ONC.US) With Buy Rating, Raises Target Price to $415Moomoo, Sep 11
BeOne Medicines stock FAQ
What is BeOne Medicines’s market cap?
BeOne Medicines’s market cap is $37.49B at the Sep 18, 2026 close of $350.84, with 104.3M shares outstanding. The shares trade on a P/E ratio of 62.9.
What is the BeOne Medicines stock forecast?
The consensus analyst 12-month price target for BeOne Medicines is $432.80, +23.4% from the last close. Of the 14 firms that rated the stock in the last 90 days, 14 rate it a buy, 0 a hold and 0 a sell. Gekko doesn’t publish price predictions of its own.
Is BeOne Medicines stock overvalued or undervalued?
On Gekko’s estimate BeOne Medicines is undervalued: the Sep 18, 2026 close of $350.84 is 7.4% below Gekko Fair Value of $379.00. Gekko Fair Value is recalculated every trading day, and a gap inside 5% either way counts as about fair value.
When does BeOne Medicines report earnings next?
BeOne Medicines is expected to report on Nov 5, 2026, before the market opens (46 days away). Analysts expect earnings of $1.90 per share on revenue of $1.75B. BeOne Medicines beat the earnings estimate in 6 of its last 8 reports, moving 4.3% on average across the report.
What is BeOne Medicines’s 52-week high and low?
BeOne Medicines’s 52-week high is $385.22 and its 52-week low is $253.95; it closed at $350.84 on Sep 18, 2026, +5.6% over the past year.
Is BeOne Medicines stock a buy right now?
Gekko describes the data; it does not make buy or sell recommendations. On the swing-trade checklist, 4 of the 5 items with data read as supportive (trend, gekkoindex, fair value and earnings risk) and 1 as a headwind (seasonality). The checklist is a description of current data, not a recommendation.
How this page works
Prices and signals update after every US market close; the GekkoIndex, Gekko Fair Value and the checklist are Gekko’s own, and the Gekko Brief is written by AI from this page’s data and checked against it before it is published. How Gekko’s data works →
See BeOne Medicines the way Gekko members do
Every GekkoIndex reading, insider trade, options bet and Congress disclosure plotted on the chart, plus the 5,800-name screener and trade planning tools.
Join 1,349 other traders using Gekko
Start Your FREE 7 Day Trial → Every feature unlocked. No credit card required.